Discussion:
A treatment with demeclocylin 600 mg daily was initiated, with a response within 6 days as natraemia increased to 137 mmol/l, with persistant efficacy at 2 months and with good tolerance ( fig. 2 ).
Introduction :
Hyponatraemia constitutes the most common hydro-electrolytic abnormality, and the determination of its cause is important for patient's management, which sometimes can include the use of a pharmacological agent. -The use of demeclocyclin has been very helpful for this lady suffering from an advanced stage lung adenocarcinoma, and who could not benefit from an aetiological treatment, which is usually associated with correction of hyponatraemias in these situations. -Demeclocyclin is an old drug, but can be still highly effective in some situations, with good tolerance. -The precise mechanism of the drug is however not well understood yet, and deserves to be elucidated in pharmacological studies.
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Conclusion:
The characteristics of this hyponatraemia were as follows : -Chronic hyponatraemia (ranging from 113 to 123 mmol/l) -Low plasma osmolarity, calculated at 250 mosm/L -High urine osmolality (sodium urinary concentration > 60 mmol/24h) -These abnormalities could not be corrected by fluid limitation alone. Clinical and biological assessment led to the diagnosis of a syndrome of paraneoplastic inappropriated secretion of antidiuretic hormone (SIADH) related to the lung cancer. Demecloclycin chlorhydrate is a tetracyclin with antagonistic properties against ADH action. The most important series of patients lasts for more than 30 years and included 11 patients (2). It should be prescribed initially at 900 to 1200 mg/day associated with moderate fluid limitation during 8 to 10 days, then 600 mg/day without fluid limitation. However in the elderly it can be initiated at 600mg/day without any fluid limitation. This drug must not be used in case of renal impairment as it can also cause renal impairment. It can be highly effective, although its mechanism of action is still unclear. The drug decreases the transcription of the AQP2 gene, associated with aquaporin-2 expression in the renal inner medulla (3). The activity is probably also due to a cyclic AMP pathway inhibition leading to a decrease in the activation of aquaporins. Another family of drugs, V2 ADH-receptors antagonists called vaptans show interesting results in case of euvolemic or hypervolemic hyponatraemias (4).
